To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, efficacy and immunogenicity of SCT510 combined with paclitaxel and
carboplatin compared with bevacizumab combined with paclitaxel and carboplatin in the
first-line treatment of locally advanced metastatic or recurrent squamous cell non-small cell
lung cancer.